放射性医薬品セラノスティックス市場(ラジオアイソトープ:テクネチウム-99、ガリウム-68、ヨウ素-131、ラジウム-223、フッ素-18、イットリウム-90、ルテチウム-177、銅-67&64、サマリウム-153、その他) - 世界の産業分析、サイズ、シェア、成長、動向、予測、2023-2031年Radiopharmaceutical Theranostics Market (Radioisotope: Technetium-99, Gallium-68, Iodine-131, Radium-223, Fluorine-18, Yttrium-90, Lutetium-177, Copper-67 & 64, Samarium-153, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 放射性医薬品セラノスティクス市場 - レポートの範囲 TMRの調査レポート「放射性医薬品セラノスティックスの世界市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、... もっと見る
サマリー放射性医薬品セラノスティクス市場 - レポートの範囲TMRの調査レポート「放射性医薬品セラノスティックスの世界市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向と機会も調査しています。本レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの期間における世界の放射性医薬品セラノスティクス市場の収益を提供します。また、2023年から2031年までの放射性医薬品セラノスティクスの世界市場の年間複合成長率(CAGR %)を掲載しています。 本レポートは、広範な調査を経て作成されました。一次調査では、主要なオピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行いました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、放射性医薬品セラノスティクス市場を把握しました。 また、インターネット上の情報源や政府機関、ウェブサイト、業界団体の統計データも二次調査の対象としています。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の放射性医薬品セラノスティクス市場の様々な属性を調査しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、放射性医薬品セラノスティクスの世界市場における競争力学の変化にも光を当てています。これらは、既存の市場関係者だけでなく、世界の放射性医薬品セラノスティックス市場への参入に関心のある企業にとっても、貴重なツールとなります。 本レポートは、世界の放射性医薬品セラノスティクス市場の競争環境について掘り下げています。世界の放射性医薬品セラノスティックス市場で活動する主要企業が特定され、それぞれの企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の開発状況、SWOTは、本レポートで紹介されている世界の放射性医薬品セラノスティクス市場のプレイヤーの属性です。 放射性医薬品セラノスティックスの世界市場レポートで回答した主要な質問 - 予測期間中に全地域で放射性医薬品セラノスティックスが生み出した売上/収益はどの程度か? - 放射性医薬品セラノスティックスの世界市場における機会は何か? - 市場の主な推進要因、阻害要因、機会、脅威は何か? - 予測期間中に最も速いCAGRで拡大するのはどの地域市場か? - 2031年に世界で最も高い収益を上げると予測されるセグメントは? - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントはどこか? - 世界市場で事業展開している各社の市場ポジションは? 放射性医薬品セラノスティックス市場 - 研究目的と研究アプローチ 放射性医薬品セラノスティックスの世界市場に関する包括的なレポートは、概要から始まり、研究の範囲と目的について説明しています。本調査の目的、市場で活動する主要ベンダーや流通業者、製品の承認に関する規制シナリオについて詳しく解説しています。 読みやすさを考慮し、本レポートは章立てでまとめられ、各セクションはより小さなものに分割されています。本レポートは、グラフと表が適切に配置された包括的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えかけています。また、過去と予測期間終了時の主要セグメントの市場シェアを比較することも可能です。 本レポートでは、世界の放射性医薬品セラノスティックス市場を製品、エンドユーザー、地域の観点から分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントごとの市場シェアを掲載しています。このような貴重な洞察により、市場関係者は、世界の放射性医薬品セラノスティクス市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。 目次1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Radiopharmaceutical Theranostics Market 4. Market Overview 4.1. Introduction 4.1.1. Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, 2017-2031 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Regulatory Scenario 5.2. Key Distribution Strategies 5.3. Pricing Analysis 5.4. Patents on Radiotracers 5.5. Technological Advancements in Radiopharmaceutical Theranostics 5.6. Radiotracer Type - Overview 5.7. COVID-19 Pandemic Impact on Industry 6. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radioisotope 6.1. Introduction & Definition 6.2. Key Findings/Developments 6.3. Market Value Forecast, by Radioisotope, 2017-2031 6.3.1. Technetium-99 6.3.2. Gallium-68 6.3.3. Iodine-131 6.3.4. Radium-223 6.3.5. Fluorine-18 6.3.6. Yttrium-90 6.3.7. Lutetium-177 6.3.8. Copper-67 & 64 6.3.9. Samarium-153 6.3.10. Others 6.4. Market Attractiveness Analysis, by Radioisotope 7. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Application 7.1. Introduction & Definition 7.2. Key Findings/Developments 7.3. Market Value Forecast, by Application, 2017-2031 7.3.1. Oncology 7.3.2. Cardiology 7.3.3. Others 7.4. Market Attractiveness Analysis, by Application 8. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Source 8.1. Introduction & Definition 8.2. Key Findings/Developments 8.3. Market Value Forecast, by Source, 2017-2031 8.3.1. Nuclear Reactors 8.3.2. Cyclotrons 8.4. Market Attractiveness Analysis, by Source 9. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Approach 9.1. Introduction & Definition 9.2. Key Findings/Developments 9.3. Market Value Forecast, by Approach, 2017-2031 9.3.1. Targeted Therapeutic (Rx) 9.3.2. Companion Diagnostic (DX) 9.4. Market Attractiveness Analysis, by Approach 10. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radiotracer Type 10.1. Introduction & Definition 10.2. Key Findings/Developments 10.3. Market Value Forecast, by Radiotracer Type, 2017-2031 10.3.1. Peptidic 10.3.2. Non-peptidic 10.4. Market Attractiveness Analysis, by Radiotracer Type 11. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by End-user 11.1. Introduction & Definition 11.2. Key Findings/Developments 11.3. Market Value Forecast, by End-user, 2017-2031 11.3.1. Hospitals 11.3.2. Academic & Research Institutes 11.3.3. Others 11.4. Market Attractiveness Analysis, by End-user 12. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Region 12.1. Key Findings 12.2. Market Value Forecast, by Region, 2017-2031 12.2.1. U.S. 12.2.2. Europe 12.2.3. Rest of the World 12.3. Market Attractiveness Analysis, by Region 13. U.S. Radiopharmaceutical Theranostics Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Radioisotope, 2017-2031 13.2.1. Technetium-99 13.2.2. Gallium-68 13.2.3. Iodine-131 13.2.4. Radium-223 13.2.5. Fluorine-18 13.2.6. Yttrium-90 13.2.7. Lutetium-177 13.2.8. Copper-67 & 64 13.2.9. Samarium-153 13.2.10. Others 13.3. Market Value Forecast, by Application, 2017-2031 13.3.1. Oncology 13.3.2. Cardiology 13.3.3. Others 13.4. Market Value Forecast, by Source, 2017-2031 13.4.1. Nuclear Reactors 13.4.2. Cyclotrons 13.5. Market Value Forecast, by Approach, 2017-2031 13.5.1. Targeted Therapeutic (Rx) 13.5.2. Companion Diagnostic (DX) 13.6. Market Value Forecast, by Radiotracer Type, 2017-2031 13.6.1. Peptidic 13.6.2. Non-peptidic 13.7. Market Value Forecast, by End-user, 2017-2031 13.7.1. Hospitals 13.7.2. Academic & Research Institutes 13.7.3. Others 13.8. Market Attractiveness Analysis 13.8.1. By Radioisotope 13.8.2. By Application 13.8.3. By Source 13.8.4. By Approach 13.8.5. By Radiotracer Type 13.8.6. By End-user 14. Europe Radiopharmaceutical Theranostics Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Radioisotope, 2017-2031 14.2.1. Technetium-99 14.2.2. Gallium-68 14.2.3. Iodine-131 14.2.4. Radium-223 14.2.5. Fluorine-18 14.2.6. Yttrium-90 14.2.7. Lutetium-177 14.2.8. Copper-67 & 64 14.2.9. Samarium-153 14.2.10. Others 14.3. Market Value Forecast, by Application, 2017-2031 14.3.1. Oncology 14.3.2. Cardiology 14.3.3. Others 14.4. Market Value Forecast, by Source, 2017-2031 14.4.1. Nuclear Reactors 14.4.2. Cyclotrons 14.5. Market Value Forecast, by Approach, 2017-2031 14.5.1. Targeted Therapeutic (Rx) 14.5.2. Companion Diagnostic (DX) 14.6. Market Value Forecast, by Radiotracer Type, 2017-2031 14.6.1. Peptidic 14.6.2. Non-peptidic 14.7. Market Value Forecast, by End-user, 2017-2031 14.7.1. Hospitals 14.7.2. Academic & Research Institutes 14.7.3. Others 14.8. Market Value Forecast, by Country/Sub-region, 2017-2031 14.8.1. Germany 14.8.2. U.K. 14.8.3. France 14.8.4. Italy 14.8.5. Spain 14.8.6. Rest of Europe 14.9. Market Attractiveness Analysis 14.9.1. By Radioisotope 14.9.2. By Application 14.9.3. By Source 14.9.4. By Approach 14.9.5. By Radiotracer Type 14.9.6. By End-user 14.9.7. By Country/Sub-region 15. Rest of the World Radiopharmaceutical Theranostics Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Radioisotope, 2017-2031 15.2.1. Technetium-99 15.2.2. Gallium-68 15.2.3. Iodine-131 15.2.4. Radium-223 15.2.5. Fluorine-18 15.2.6. Yttrium-90 15.2.7. Lutetium-177 15.2.8. Copper-67 & 64 15.2.9. Samarium-153 15.2.10. Others 15.3. Market Value Forecast, by Application, 2017-2031 15.3.1. Oncology 15.3.2. Cardiology 15.3.3. Others 15.4. Market Value Forecast, by Source, 2017-2031 15.4.1. Nuclear Reactors 15.4.2. Cyclotrons 15.5. Market Value Forecast, by Approach, 2017-2031 15.5.1. Targeted Therapeutic (Rx) 15.5.2. Companion Diagnostic (DX) 15.6. Market Value Forecast, by Radiotracer Type, 2017-2031 15.6.1. Peptidic 15.6.2. Non-peptidic 15.7. Market Value Forecast, by End-user, 2017-2031 15.7.1. Hospitals 15.7.2. Academic & Research Institutes 15.7.3. Others 15.8. Market Attractiveness Analysis 15.8.1. By Radioisotope 15.8.2. By Application 15.8.3. By Source 15.8.4. By Approach 15.8.5. By Radiotracer Type 15.8.6. By End-user 16. Competition Landscape 16.1. Market Player Competition Matrix (by tier and size of companies) 16.2. Market Share Analysis, by Company (2022) 16.3. Company Profiles 16.3.1. Advanced Accelerator Applications (Novartis AG) 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.1.2. Product Portfolio 16.3.1.3. Financial Overview 16.3.1.4. SWOT Analysis 16.3.1.5. Strategic Overview 16.3.2. Aurobindo Pharma 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2.2. Product Portfolio 16.3.2.3. Financial Overview 16.3.2.4. SWOT Analysis 16.3.2.5. Strategic Overview 16.3.3. Bayer AG 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.3.2. Product Portfolio 16.3.3.3. Financial Overview 16.3.3.4. SWOT Analysis 16.3.3.5. Strategic Overview 16.3.4. Blue Earth Diagnostics (Bracco) 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.4.2. Product Portfolio 16.3.4.3. Financial Overview 16.3.4.4. SWOT Analysis 16.3.4.5. Strategic Overview 16.3.5. Cardinal Health 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.5.2. Product Portfolio 16.3.5.3. Financial Overview 16.3.5.4. SWOT Analysis 16.3.5.5. Strategic Overview 16.3.6. Clarity Pharmaceuticals 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.6.2. Product Portfolio 16.3.6.3. Financial Overview 16.3.6.4. SWOT Analysis 16.3.6.5. Strategic Overview 16.3.7. GE Healthcare 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.7.2. Product Portfolio 16.3.7.3. Financial Overview 16.3.7.4. SWOT Analysis 16.3.7.5. Strategic Overview 16.3.8. Jubliant Radiopharma 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.8.2. Product Portfolio 16.3.8.3. Financial Overview 16.3.8.4. SWOT Analysis 16.3.8.5. Strategic Overview 16.3.9. Lantheus Medical Imaging 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.9.2. Product Portfolio 16.3.9.3. Financial Overview 16.3.9.4. SWOT Analysis 16.3.9.5. Strategic Overview 16.3.10. Navidea Biopharmaceuticals, Inc. 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.10.2. Product Portfolio 16.3.10.3. Financial Overview 16.3.10.4. SWOT Analysis 16.3.10.5. Strategic Overview 16.3.11. SOFIE 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.11.2. Product Portfolio 16.3.11.3. Financial Overview 16.3.11.4. SWOT Analysis 16.3.11.5. Strategic Overview 16.3.12. Telix Pharmaceuticals 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.12.2. Product Portfolio 16.3.12.3. Financial Overview 16.3.12.4. SWOT Analysis 16.3.12.5. Strategic Overview 図表リストList of TablesTable 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031 Table 02: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 03: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031 Table 04: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031 Table 05: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031 Table 06: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 07: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Region, 2017–2031 Table 08: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031 Table 09: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 10: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031 Table 11: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031 Table 12: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031 Table 13: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 14: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 15: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031 Table 16: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 17: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031 Table 18: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031 Table 19: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031 Table 20: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 21: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031 Table 22: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 23: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031 Table 24: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031 Table 25: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031 Table 26: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
SummaryRadiopharmaceutical Theranostics Market – Scope of Report Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Radiopharmaceutical Theranostics Market 4. Market Overview 4.1. Introduction 4.1.1. Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, 2017-2031 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Regulatory Scenario 5.2. Key Distribution Strategies 5.3. Pricing Analysis 5.4. Patents on Radiotracers 5.5. Technological Advancements in Radiopharmaceutical Theranostics 5.6. Radiotracer Type - Overview 5.7. COVID-19 Pandemic Impact on Industry 6. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radioisotope 6.1. Introduction & Definition 6.2. Key Findings/Developments 6.3. Market Value Forecast, by Radioisotope, 2017-2031 6.3.1. Technetium-99 6.3.2. Gallium-68 6.3.3. Iodine-131 6.3.4. Radium-223 6.3.5. Fluorine-18 6.3.6. Yttrium-90 6.3.7. Lutetium-177 6.3.8. Copper-67 & 64 6.3.9. Samarium-153 6.3.10. Others 6.4. Market Attractiveness Analysis, by Radioisotope 7. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Application 7.1. Introduction & Definition 7.2. Key Findings/Developments 7.3. Market Value Forecast, by Application, 2017-2031 7.3.1. Oncology 7.3.2. Cardiology 7.3.3. Others 7.4. Market Attractiveness Analysis, by Application 8. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Source 8.1. Introduction & Definition 8.2. Key Findings/Developments 8.3. Market Value Forecast, by Source, 2017-2031 8.3.1. Nuclear Reactors 8.3.2. Cyclotrons 8.4. Market Attractiveness Analysis, by Source 9. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Approach 9.1. Introduction & Definition 9.2. Key Findings/Developments 9.3. Market Value Forecast, by Approach, 2017-2031 9.3.1. Targeted Therapeutic (Rx) 9.3.2. Companion Diagnostic (DX) 9.4. Market Attractiveness Analysis, by Approach 10. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radiotracer Type 10.1. Introduction & Definition 10.2. Key Findings/Developments 10.3. Market Value Forecast, by Radiotracer Type, 2017-2031 10.3.1. Peptidic 10.3.2. Non-peptidic 10.4. Market Attractiveness Analysis, by Radiotracer Type 11. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by End-user 11.1. Introduction & Definition 11.2. Key Findings/Developments 11.3. Market Value Forecast, by End-user, 2017-2031 11.3.1. Hospitals 11.3.2. Academic & Research Institutes 11.3.3. Others 11.4. Market Attractiveness Analysis, by End-user 12. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Region 12.1. Key Findings 12.2. Market Value Forecast, by Region, 2017-2031 12.2.1. U.S. 12.2.2. Europe 12.2.3. Rest of the World 12.3. Market Attractiveness Analysis, by Region 13. U.S. Radiopharmaceutical Theranostics Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Radioisotope, 2017-2031 13.2.1. Technetium-99 13.2.2. Gallium-68 13.2.3. Iodine-131 13.2.4. Radium-223 13.2.5. Fluorine-18 13.2.6. Yttrium-90 13.2.7. Lutetium-177 13.2.8. Copper-67 & 64 13.2.9. Samarium-153 13.2.10. Others 13.3. Market Value Forecast, by Application, 2017-2031 13.3.1. Oncology 13.3.2. Cardiology 13.3.3. Others 13.4. Market Value Forecast, by Source, 2017-2031 13.4.1. Nuclear Reactors 13.4.2. Cyclotrons 13.5. Market Value Forecast, by Approach, 2017-2031 13.5.1. Targeted Therapeutic (Rx) 13.5.2. Companion Diagnostic (DX) 13.6. Market Value Forecast, by Radiotracer Type, 2017-2031 13.6.1. Peptidic 13.6.2. Non-peptidic 13.7. Market Value Forecast, by End-user, 2017-2031 13.7.1. Hospitals 13.7.2. Academic & Research Institutes 13.7.3. Others 13.8. Market Attractiveness Analysis 13.8.1. By Radioisotope 13.8.2. By Application 13.8.3. By Source 13.8.4. By Approach 13.8.5. By Radiotracer Type 13.8.6. By End-user 14. Europe Radiopharmaceutical Theranostics Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Radioisotope, 2017-2031 14.2.1. Technetium-99 14.2.2. Gallium-68 14.2.3. Iodine-131 14.2.4. Radium-223 14.2.5. Fluorine-18 14.2.6. Yttrium-90 14.2.7. Lutetium-177 14.2.8. Copper-67 & 64 14.2.9. Samarium-153 14.2.10. Others 14.3. Market Value Forecast, by Application, 2017-2031 14.3.1. Oncology 14.3.2. Cardiology 14.3.3. Others 14.4. Market Value Forecast, by Source, 2017-2031 14.4.1. Nuclear Reactors 14.4.2. Cyclotrons 14.5. Market Value Forecast, by Approach, 2017-2031 14.5.1. Targeted Therapeutic (Rx) 14.5.2. Companion Diagnostic (DX) 14.6. Market Value Forecast, by Radiotracer Type, 2017-2031 14.6.1. Peptidic 14.6.2. Non-peptidic 14.7. Market Value Forecast, by End-user, 2017-2031 14.7.1. Hospitals 14.7.2. Academic & Research Institutes 14.7.3. Others 14.8. Market Value Forecast, by Country/Sub-region, 2017-2031 14.8.1. Germany 14.8.2. U.K. 14.8.3. France 14.8.4. Italy 14.8.5. Spain 14.8.6. Rest of Europe 14.9. Market Attractiveness Analysis 14.9.1. By Radioisotope 14.9.2. By Application 14.9.3. By Source 14.9.4. By Approach 14.9.5. By Radiotracer Type 14.9.6. By End-user 14.9.7. By Country/Sub-region 15. Rest of the World Radiopharmaceutical Theranostics Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Radioisotope, 2017-2031 15.2.1. Technetium-99 15.2.2. Gallium-68 15.2.3. Iodine-131 15.2.4. Radium-223 15.2.5. Fluorine-18 15.2.6. Yttrium-90 15.2.7. Lutetium-177 15.2.8. Copper-67 & 64 15.2.9. Samarium-153 15.2.10. Others 15.3. Market Value Forecast, by Application, 2017-2031 15.3.1. Oncology 15.3.2. Cardiology 15.3.3. Others 15.4. Market Value Forecast, by Source, 2017-2031 15.4.1. Nuclear Reactors 15.4.2. Cyclotrons 15.5. Market Value Forecast, by Approach, 2017-2031 15.5.1. Targeted Therapeutic (Rx) 15.5.2. Companion Diagnostic (DX) 15.6. Market Value Forecast, by Radiotracer Type, 2017-2031 15.6.1. Peptidic 15.6.2. Non-peptidic 15.7. Market Value Forecast, by End-user, 2017-2031 15.7.1. Hospitals 15.7.2. Academic & Research Institutes 15.7.3. Others 15.8. Market Attractiveness Analysis 15.8.1. By Radioisotope 15.8.2. By Application 15.8.3. By Source 15.8.4. By Approach 15.8.5. By Radiotracer Type 15.8.6. By End-user 16. Competition Landscape 16.1. Market Player Competition Matrix (by tier and size of companies) 16.2. Market Share Analysis, by Company (2022) 16.3. Company Profiles 16.3.1. Advanced Accelerator Applications (Novartis AG) 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.1.2. Product Portfolio 16.3.1.3. Financial Overview 16.3.1.4. SWOT Analysis 16.3.1.5. Strategic Overview 16.3.2. Aurobindo Pharma 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2.2. Product Portfolio 16.3.2.3. Financial Overview 16.3.2.4. SWOT Analysis 16.3.2.5. Strategic Overview 16.3.3. Bayer AG 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.3.2. Product Portfolio 16.3.3.3. Financial Overview 16.3.3.4. SWOT Analysis 16.3.3.5. Strategic Overview 16.3.4. Blue Earth Diagnostics (Bracco) 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.4.2. Product Portfolio 16.3.4.3. Financial Overview 16.3.4.4. SWOT Analysis 16.3.4.5. Strategic Overview 16.3.5. Cardinal Health 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.5.2. Product Portfolio 16.3.5.3. Financial Overview 16.3.5.4. SWOT Analysis 16.3.5.5. Strategic Overview 16.3.6. Clarity Pharmaceuticals 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.6.2. Product Portfolio 16.3.6.3. Financial Overview 16.3.6.4. SWOT Analysis 16.3.6.5. Strategic Overview 16.3.7. GE Healthcare 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.7.2. Product Portfolio 16.3.7.3. Financial Overview 16.3.7.4. SWOT Analysis 16.3.7.5. Strategic Overview 16.3.8. Jubliant Radiopharma 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.8.2. Product Portfolio 16.3.8.3. Financial Overview 16.3.8.4. SWOT Analysis 16.3.8.5. Strategic Overview 16.3.9. Lantheus Medical Imaging 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.9.2. Product Portfolio 16.3.9.3. Financial Overview 16.3.9.4. SWOT Analysis 16.3.9.5. Strategic Overview 16.3.10. Navidea Biopharmaceuticals, Inc. 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.10.2. Product Portfolio 16.3.10.3. Financial Overview 16.3.10.4. SWOT Analysis 16.3.10.5. Strategic Overview 16.3.11. SOFIE 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.11.2. Product Portfolio 16.3.11.3. Financial Overview 16.3.11.4. SWOT Analysis 16.3.11.5. Strategic Overview 16.3.12. Telix Pharmaceuticals 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.12.2. Product Portfolio 16.3.12.3. Financial Overview 16.3.12.4. SWOT Analysis 16.3.12.5. Strategic Overview List of Tables/GraphsList of TablesTable 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031 Table 02: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 03: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031 Table 04: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031 Table 05: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031 Table 06: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 07: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Region, 2017–2031 Table 08: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031 Table 09: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 10: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031 Table 11: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031 Table 12: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031 Table 13: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 14: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 15: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031 Table 16: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 17: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031 Table 18: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031 Table 19: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031 Table 20: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031 Table 21: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031 Table 22: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031 Table 23: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031 Table 24: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031 Table 25: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031 Table 26: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医薬)の最新刊レポート
Transparency Market Research社の製薬分野での最新刊レポート
本レポートと同じKEY WORD(industry)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/22 10:26 155.52 円 163.34 円 198.56 円 |